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Background Trial participation decisions are often influenced by
expectations of potential benefit. Attention has focused on trial par-
ticipation as a means of securing something seen as desirable, such
as experimental treatment. In contrast, we consider a case in which
one trial arm involved receiving less than usual care. We explore
how this influenced participants’ decisions to participate.
Methods Semi-structured interviews with 29 women participating in
a pilot trial comparing invasive urodynamic testing (typically normal
care) to basic clinical assessment with non-invasive tests, prior to
surgical treatment for stress urinary incontinence. Analysis was
based on the constant comparative method.
Results Invasive tests were something many were aware of and wor-
ried about. Participants understood that trial participation meant
they might avoid having these tests, and for about one-third, this
was the primary factor motivating participation. A further third
mentioned they were not looking forward to tests (if allocated to
them) or were lucky to have missed them (if allocated to basic clini-
cal assessment). None of the women appeared to have discussed
their desire to avoid having invasive tests with their clinicians.
Conclusions In contrast to cases in which trial participation is moti-
vated by the wish to secure an intervention not otherwise available,
this study reports the opposite – trial participation as an opportunity
to avoid having something regarded as undesirable. The option to
decline a particular intervention should always be available, and care
must be taken to ensure that potential participants are aware that
trial participation is not the only possible means of avoidance.
Background
Decisions to participate in clinical trials are
often heavily influenced by expectations of
potential benefit, at both a societal and individ-
ual level,1–9 and eligible individuals may be
unwilling to be recruited because of the risk of
being randomized to receive a placebo.10 In
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terms of individual benefit, most attention to
date has been focused on trial participation as a
means of securing something that the participant
wishes to have, such as access to a new treat-
ment, or a perceived better standard of care. As
an example, McCann et al.7 interviewing partici-
pants in a trial comparing medical and surgical
interventions for gastro-oesophageal reflux dis-
ease, while emphasizing that willingness to
contribute to the collective good was a key moti-
vating factor, also found ‘conditional altruism’
evidenced by a feeling that trial participation
might bring: an opportunity for closer specialist
review; (faster) access to surgery; and more care-
ful monitoring of disease progress.
Motivations based on potentially unrealistic
or misinterpreted expectations of individual ben-
efit may be problematic,11 particularly given that
evidence shows that although trials are only con-
ducted when there are reasonable grounds to
expect benefit from the trialled interventions
(and no evidence of harm), new treatments are
found to be better than existing ones only just
over half the time, and new treatments may
indeed perform less well than existing ones.12 In
addition, there seems only weak evidence to sug-
gest that participation in clinical trials per se has
a positive effect on individual participants’ out-
comes and that the effect seems to be larger in
trials where an effective treatment already exists
and is included in the trial protocol.13,14
While the current literature on this topic con-
sists of cases in which motivation to participate
is driven, at least in part, by a desire to secure
access to something that the participant wishes
to have, this study looks at a new and interesting
twist in which one trial arm comprised receiving
something less than usual care. We explore how
this influenced participants’ decisions to take
part in the trial.
The INVESTIGATE-I study was a mixed
methods feasibility study including a pragmatic
multicentre ‘rehearsal’ pilot randomized con-
trolled trial (RCT) of invasive urodynamic
testing compared to basic clinical assessment
before surgical treatment for stress urinary
incontinence in women; it was funded under the
UK National Institute for Health Research
Health Technology Assessment programme
(NIHR-HTA) programme.15,16 Urinary inconti-
nence, while rarely life-threatening, may
seriously influence the physical, psychological
and social well-being of affected individuals.
Prevalence figures range from 5 to 69% in
women 15 years and older, with most studies
reporting prevalence in the range 25–45%.17
More severe urinary incontinence is reported in
4–7% of women under the age of 65, and around
five million women over 20 years of age may be
affected in England and Wales.18
Several methods are used in the assessment of
urinary incontinence in order to evaluate func-
tion of the lower urinary tract and guide
decisions about the most appropriate way to
manage the condition. These include non-
invasive tests (such as free urine flow rate and
post-void residual volume), but some tests
require catheterization (such as conventional
cystometry or videourodynamics) and are there-
fore regarded as invasive. Such invasive tests
involve having the bladder filled, provocation
tests to show leakage and then voiding, all in the
presence of healthcare professionals.
Despite its widespread clinical use over four
decades, the appropriate position of invasive
urodynamic testing in the diagnostic pathway
remains unclear. The UK National Institute
for Health and Care Excellence (NICE),19 the
NIHR-HTA programme,20 the Cochrane Col-
laboration21 and the International Consultations
on Incontinence22 have all undertaken systematic
reviews on the subject and all emphasize the lack
of high-quality primary research confirming
clinical utility.
While serious morbidity associated with inva-
sive urodynamic testing is rare, up to 20% of
women with sterile urine prior to investigation
may develop bacteriological evidence of urinary
tract infection subsequently.23–26 Anxiety and
embarrassment on the part of those undergoing
invasive urodynamic testing are commonly
reported,27 although not all women will experi-
ence high anxiety levels.28 Over a quarter of
women experience pain during investigation.29
In England, the current guidance from NICE
suggests that invasive urodynamic testing is not
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required prior to conservative treatments and
that, while it may be needed in more complex
clinical scenarios, there is no evidence to support
its use prior to surgery where the diagnosis of
stress urinary incontinence is likely based
on clinical assessment alone.30 Within the
INVESTIGATE-I study protocol, invasive
urodynamic testing was described as the inter-
vention arm, and clinical assessment with non-
invasive tests, but without invasive testing, as
the control arm. It should be noted, however,
that the use of invasive urodynamic testing for
these patients is currently commonplace in the
UK, and indeed could be more accurately
described as ‘usual care’.31–33 We recognize that
this is something of an anomaly, but felt at the
time of protocol development that the more
active investigation strategy should be desig-
nated as the intervention and the less active as
the control.
As part of our pilot work for a possible future
RCT assessing the value of invasive urodynamic
testing in patients with urinary incontinence, we
sought to explore women’s views on the accept-
ability of randomization either to invasive
testing or to clinical assessment alone (without
invasive testing).
Methods
We conducted semi-structured interviews with
women who had participated in a pilot trial
comparing invasive urodynamic testing to basic
clinical assessment with non-invasive tests prior
to surgical treatment for urinary incontinence.15
While we also invited all women who did not
agree to join the pilot trial (59) as soon as possi-
ble thereafter for interview, none agreed to
do so.
Interviews were carried out to explore
women’s understandings and experiences of the
study (including the initial approach, baseline
data collection and 6-month follow-up), the con-
sent process and their decision to participate
(including how they had made the decision, how
easy or difficult they had found this, who they
had discussed it with), and any perceived barri-
ers to or facilitators of participation in a future
definitive RCT. Purposive sampling was used to
include women from a range of ages, trial partic-
ipation status (randomized and retained to final
follow-up; randomized but did not provide full
follow-up data), allocation status (invasive uro-
dynamic testing or basic assessment), treatment
received (surgery or conservative management)
and study site.
Women were approached at the end of the
trial, so as to capture both their reasons for
agreeing to participate and their overall experi-
ence of taking part in the study (interviews
typically took place 10 months after the decision
to participate was made). A specific participant
information leaflet was provided for the inter-
view study, and written consent was obtained
from all interviewees. The interviews were car-
ried out face to face by an expert qualitative
interviewer (see Acknowledgements) and were
audio-recorded and transcribed verbatim.
The interviews were semi-structured, using a
prompt guide with broad topic areas, but the
emphasis was on encouraging women to discuss
their own perspectives freely and allowing them
to raise issues that were important to them. The
interviewer prompted as appropriate to ensure
that all views were fully explained, and the
meaning of participants’ responses clear. The
prompt guide was developed from a literature
review and discussions within the project team
and was modified as the interviews progressed to
incorporate issues raised by earlier interviewees.
Data collection continued until saturation of
themes was reached and interviews no longer
generated new concepts. Analysis was completed
by ES and NA based on the constant compara-
tive method,34 and aided by NVivo 10 (QSR
International, Warrington, UK) qualitative soft-
ware. Transcripts were read three to four times
and open codes initially applied line by line to
the data to represent the meaning or significance
of each sentence or group of sentences. Genera-
tion of the open codes proceeded sequentially,
with no attempt at this stage to impose any
framework on the data. The open codes were
then incrementally grouped into organizing cate-
gories or themes. These categories were modified
and checked constantly as further open codes
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were incorporated as analysis proceeded. When
categories had been created to express all of the
open codes, explicit specifications were written
for each of the categories to assist in determining
under what circumstances data should be
assigned to any given category. The categories
and their specifications (the coding scheme) were
then programmed into NVivo 10 software. The
coding scheme was then used to process the data
set systematically by assigning each section of
text to a category, according to the cate-
gory specifications.
For research governance purposes, the
INVESTIGATE-I study as a whole (including
these patient interviews) was reviewed by New-
castle & North Tyneside 1 Research Ethics
Committee and given a favourable opinion (Ref
10/H0906/76). NHS R&D approval was pro-
vided by each participating trial centre.
Results
Details of the sample
A total of 111 pilot trial participants were ini-
tially invited to take part in an interview; 36
women indicated they were willing to be inter-
viewed. Of these, 29 were interviewed, two
withdrew from the interview study before the
interview could be arranged, one had moved and
so was no longer covered by our research gover-
nance approvals, and four were not interviewed
as they were from groups already well repre-
sented in the sample. Interviewees were between
35 and 75 years of age, came from five of the
seven trial centres and included participants
from both trial arms (16 received invasive test-
ing; 13 received basic clinical assessment).
Twenty-seven women subsequently had surgery,
one received non-surgical treatment, and one
declined surgery.
Awareness of invasive urodynamic testing, and a
wish to avoid it
The specific nature of the trial and the interven-
tion being assessed was an important factor for
many women when making decisions about par-
ticipation. The possibility of having invasive
urodynamic testing (which tends to constitute
usual care in the UK) performed prior to any sur-
gical treatment was something that many were
already aware of, and worried about, prior to
being invited to participate in the trial. This
awareness had typically come either through their
own prior personal experience or through hearing
about invasive urodynamic testing from friends
and family members who had undergone the test
themselves. Concerns typically centred on issues
around embarrassment and pain or discomfort.
I had spoken to other people who had had the
same operation as I was going to have and they
had told me that the worst part about the opera-
tion, apart from being in hospital and having the
operation and the discomfort afterwards, was hav-
ing the tests beforehand and they said it just felt
like there was a lot of discomfort and, you know,
it’s just not a very nice experience. (Interviewee 08,
basic clinical assessment)
Well the diagnostic is a bit embarrassing I think,
erm [. . .] it’s embarrassing enough to have a, a sort
of situation like this [incontinence] but when you
have got to go and confront people with it as well.
(Interviewee 14, basic clinical assessment)
Avoidance as a primary motivator for
participation
The possibility of avoiding having invasive uro-
dynamic tests was discussed as the primary
motivation to participate in the trial by about
one-third of the women we interviewed:
There was a 50:50 chance I wouldn’t have to have
urodynamics, which I really didn’t want to have.
(Interviewee 01, urodynamics)
What really worried me was having all the bladder
tests beforehand because I felt quite stressed about
things like that and I was told there was a chance
if I entered the trial I might still have to have them
but there was a chance I might not have to have
them, which was quite a good incentive. (Intervie-
wee 05, basic clinical assessment)
While typically discussed as wishing to avoid
a form of testing that they would find unpleasant
in its own right, some women also talked about
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wishing to avoid invasive testing as a means of
securing quicker access to surgery for their conti-
nence problems:
CAN YOU REMEMBERWHAT YOUR FIRST
REACTION WAS WHEN YOU WERE TOLD
ABOUT THE TRIAL?
Thought great. . .Because I had heard that it was
quite long winded and a slow process through
various different tests and there was one of the
tests that I had heard was quite horrible as well I
can’t remember what it’s called now, but there
was, and sometimes it sort of just took sort of 6
or 9 months to even get that far, you know and
then it was still sort of on-going so when they
said, you know we are doing this trial because we
are not sure whether that’s actually necessary and
if you are chosen for the trial you bypass all that I
just thought great (laughs) because obviously it’s
not something you want to keep having a problem
with, you want to get it sorted as quickly as possi-
ble don’t you? (Interviewee 10, basic clinical
assessment)
Reactions to trial allocation
In addition to those who discussed avoidance of
invasive testing as the primary motivation for
their trial participation, a further third of those
interviewed discussed invasive testing in negative
terms when talking about their trial allocation.
Those randomly allocated to receive invasive
testing stressed how they were not looking for-
ward to the tests and hoped they might have
been able to avoid them:
We were laughing and I said oh I am bound to be
picked to do it [IUT] because (laughs) it’s one of
them things you think, God I hope I am not picked
to do it and then they go oh yes you have been
picked to do it. (Interviewee 07, urodynamics)
She asked a few questions, you know, am I sure I
want to join the study and things? And I said yeah,
it seems absolutely fine, I said anything not to
have, see if I get a 50/50 chance not to have the
test, you know!
WERE YOU NOT LOOKING FORWARD TO
THOSE TESTS THEN?
No, I wasn’t!
YOU WERE ALLOCATED URODYNAMICS
THOUGH, WEREN’T YOU?
Yes, unfortunately, but never mind. (Interviewee
31, urodynamics)
Those allocated to the trial arm not receiving
invasive tests typically reported being pleased
with this outcome, and felt they were lucky to
have missed them:
And I was probably [one of] the lucky ones
because I didn’t have to the test (laughs). . .And I
have heard that the test, that it can be quite embar-
rassing. (Interviewee 04, basic clinical assessment)
The trials nurse rang me and informed me that I
had actually managed to avoid the invasive
research.
AND HOWDID YOU FEEL ABOUT THAT?
Elated! I really was quite elated because it did
sound quite uncomfortable but as I said, I would
have gone through with it, had I had to. (Intervie-
wee 28, basic clinical assessment)
The potential to avoid invasive testing outside of
the trial context
It is interesting given the strong preference
expressed by some women to avoid invasive test-
ing that none mentioned the possibility of doing
so outside of the trial context. Certainly, none of
the women we interviewed appeared to have dis-
cussed their desire to avoid having invasive
urodynamic testing with their clinicians prior to
receiving the invitation to participate.
One participant who discussed the possibility
of avoiding invasive testing as the primary moti-
vator for her trial participation had significant
concerns about taking part in the trial. She
talked about her participation in a previous
research study when pregnant, and appeared to
have found this very traumatic. However, her
wish to avoid invasive testing was sufficiently
strong to overcome this and, despite having
promised herself she would never participate
in research again, she did agree to join
INVESTIGATE-I in order to do so:
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WHAT WAS YOUR FIRST REACTION
WHEN YOU WERE TOLD ABOUT THE
TRIAL FIRST OF ALL?
Probably to not take part, because I promised
myself I’d never take part in any trials. I’d previ-
ously been involved in a trial when I was pregnant
with my first child and it didn’t affect the delivery
but we were at a different hospital than we
would’ve chosen had we not been part of that trial
and I had a very traumatic delivery which caused
the incontinence, and it was quite. . .caused quite a
lot of damage, well my child had brain injuries as a
result, and so I was quite. . .I promised myself I’d
never get involved in a trial again [. . .] but the big
carrot was potentially not having the bladder func-
tion tests.
SO DID YOU THINK THEN THAT YOU, IF
YOU’D GONE DOWN A ROUTE OF NOT
BEING PART OF THE STUDY THAT YOU
WOULD HAVE DEFINITELY HAD TO
HAVE THE BLADDER FUNCTION TESTS?
Yes, I would have done. (Interviewee 05, basic
clinical assessment)
Discussion
Being asked to participate in a clinical trial
comparing invasive urodynamic testing to basic
clinical assessment with non-invasive tests sur-
faced a previously undeclared preference for
avoiding the invasive urodynamic tests that tend
to comprise usual care. Therefore, while the
current literature on personal benefit as a moti-
vation for trial participation is often focused on
the wish to secure something, this paper has
demonstrated that in some cases trial participa-
tion can be motivated by a wish to avoid having
something that the potential participant regards
as undesirable. Of course, one might equally
describe this as a desire to secure a non-invasive
investigation strategy. However, as we have
shown in the introduction, despite NICE guid-
ance to the contrary, invasive urodynamic
testing is in essence current ‘usual care’ in the
UK.31–33 It was also noted that, while several
women expressed a wish to avoid invasive
testing, or relief that they had performed so,
none expressed a positive wish to undergo a
non-invasive investigation strategy. We opine
therefore that avoidance is the issue here.
Recognizing the potential for trial participa-
tion to be a means of avoidance highlights some
important issues. None of the women we inter-
viewed appeared to have discussed their desire to
avoid having invasive urodynamic testing with
their clinicians prior to receiving the invitation
to participate. This is mirrored by the clinician-
focused elements of the INVESTIGATE-I pilot
study in which there was often a clear preference
on the part of clinicians for use of invasive
urodynamic testing (not always for reasons of
pure clinical utility) and importantly no mention
of involving patients themselves in decisions
about whether or not to do so in any particular
clinical case.32,33 It is an interesting paradox that
agreeing to randomization, which is so often
seen as a ceding of control over decision making,
in this case was perceived by women as a poten-
tial way of gaining a degree of control over what
happened to them.
That many patients seemingly had not
thought it possible to discuss their preference to
avoid invasive urodynamic testing with their
clinicians outside of the trial context is perhaps
not surprising as it may be difficult for patients
to find information and act to try to secure their
preferences, not least because many women hav-
ing invasive urodynamic testing report not
feeling fully informed about it or fully under-
standing it beforehand.35 In many cases, it
would seem unlikely that invasive urodynamic
testing is ‘what women want’.36 This undisclosed
preference to avoid invasive tests, coupled with
NICE’s current position that there is no evidence
to support the use of these prior to surgery
where the diagnosis of stress urinary inconti-
nence is likely based on clinical assessment
alone, would seem to suggest a need to move
towards use of less invasive tests in these simpler
cases, and to more fully involve patients in mak-
ing decisions about possible use of invasive tests
in more complex cases. This latter would mean
presenting all options explicitly and in an unbi-
ased way in order to enable patients to make an
informed decision – something that may require
clinicians to significantly change their approach.
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In relation to trials, patient preferences can be
understood as evaluations of an intervention in
terms of its desirability both in relation to expec-
tations about the process and outcome of any
intervention and the perceived value of these.
Taking account of patient preferences within tri-
als is not simple, and the effects these can have
on any trial’s conduct and the validity of the
resulting data are complex.37 For example, a
separate urinary incontinence trial led by PH
compared colposuspension with tension-free
vaginal tape.38 The issue in this case was that
there was differential drop out prior to surgery,
with more participants dropping out of the more
invasive colposuspension arm. The exploration
of the biases this may have caused was complex.
In the case of INVESTIGATE-I, it is worth not-
ing that of 11 participants withdrawing from the
study, 5 did so within 6 weeks of randomization;
one was randomized in error, but the other four
had been randomized to receive invasive urody-
namic testing.15
While some interventions may only be avail-
able within the context of a trial (such as
experimental tests or treatments), the option to
decline a particular intervention (whether thera-
peutic or diagnostic) should always be available
to patients and care must be taken to ensure that
potential participants are aware that trial partic-
ipation is not the only possible means of
avoidance. While there has been a significant
focus in recent years on the need to move
towards shared decision making between
patients and clinicians, this is not yet the norm
within health care and is perhaps most usually
associated with treatment interventions rather
than the investigations and tests that may be
involved within the preceding diagnostic process.
This study has some limitations. It appears
that the possibility of avoiding invasive testing
was a motivating factor in deciding to join the
trial for a proportion of women, in the knowl-
edge that this gave them a 50% chance of
avoiding investigation. We also invited for inter-
view all women (59) who, while eligible and
invited, had declined to participate in the
INVESTIGATE-I pilot trial; none were willing
to take part. We therefore do not know to what
extent preferences around invasive testing may
have been a factor in their decision making.
Additionally, we opted to invite participants for
interview at the end of the trial, so as to capture
both their reasons for agreeing to participate
and their overall experience of taking part in
the study. This inevitably meant that inter-
views took place sometime (typically about
10 months) after the decision about whether or
not to participate in the trial had been taken.
Issues of recall bias and/or post hoc rationaliza-
tion cannot therefore be ruled out.
Notwithstanding these limitations, this study
does suggest some important areas for consider-
ation and future research. Perhaps the most
important of these is the need to ensure that
potential participants are aware that trial partic-
ipation is not the only possible means of
avoidance, although how this can best be
achieved in practice will require further work.
The official guidance in the UK on providing
information and gaining informed consent for
research suggests that interactive questioning of
potential participants within the consent process
can aid understanding and may highlight areas
that potential participants have misunder-
stood.39 It may be that patients are not aware of
the possibility to decline any particular interven-
tion, particularly if this relates to diagnostic
testing rather than treatment, and so understand
trial participation to be the only possible means
of avoidance. Those taking informed consent in
these contexts should be alert to this possibility
and be prepared to advise patients accordingly.
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